What is Brief History of Perrigo Company Company?

Perrigo Company Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What is the history of Perrigo Company?

Perrigo Company began in 1887 in Allegan, Michigan, founded by Luther Perrigo. Initially, the company focused on packaging and distributing patented medicines and household items to country stores. This early venture aimed to make health products more accessible and affordable.

A key innovation was the company's adoption of the private label concept, allowing stores to put their own names on products. This strategy helped build customer loyalty and differentiate the company in the market.

From its beginnings as L. Perrigo Company, repackaging items like epsom salts, it grew into a major pharmaceutical entity. Today, Perrigo Company plc is headquartered in Dublin, Ireland, with operational headquarters in Grand Rapids, Michigan. It is the world's largest manufacturer of OTC healthcare products and a leading supplier of store-brand infant formulas. In fiscal year 2024, the company reported net sales of $4.37 billion and employed 8,379 people globally. Perrigo supplies over 50% of the U.S. private-label OTC market by volume, showcasing its significant market presence. For a deeper understanding of its operational environment, consider a Perrigo Company PESTEL Analysis.

The Perrigo Company's journey began in 1887 in Allegan, Michigan, established by brothers Luther and Charles Perrigo. Luther, already involved in a general store and apple-drying, saw a market gap for affordable health and household items in rural areas, aiming to package and distribute these essentials.

The Founding Vision

Luther Perrigo's initial concept was to supply rural country stores with accessible and affordable health and household products. This foresight laid the groundwork for what would become a significant player in the consumer healthcare industry.

• Founded in 1887 in Allegan, Michigan.
• Founded by brothers Luther and Charles Perrigo.
• Initial focus on providing products to rural country stores.
• Perrigo company early years were marked by innovation in product distribution.

The core of the early business model was the innovative 'private label' strategy. Perrigo offered to imprint the individual store's name on products like epsom salts, sweet oil, and bay rum at no extra charge. This approach aimed to foster customer loyalty for retailers and ensure that consumers had access to cost-effective health solutions. The company, initially named L. Perrigo Company, officially incorporated in 1892, with Luther Perrigo taking the helm as president. Funding for this venture likely came from Luther's personal finances or local investments, typical for businesses of that era. A key challenge during this formative period was establishing a dependable supply chain and distribution network to reach a scattered customer base and build trust in their private-label offerings. The company remained family-owned for approximately 90 years, with Luther's grandchildren, William L. Tripp and later Bill Tripp Jr., assuming leadership in 1967 and 1969, respectively, continuing the Perrigo company legacy.

Perrigo Company SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Perrigo's journey from a repackager of home remedies to a manufacturer of affordable healthcare products began with a strategic shift in the mid-1930s. This evolution was underpinned by establishing its first manufacturing facility in Allegan, Michigan, in 1921, and expanding production with a second plant in 1936.

From Repackaging to Manufacturing

Perrigo's early growth was characterized by a move from simply repackaging existing remedies to actively manufacturing its own affordable healthcare products. This transition was significantly boosted by securing its first major private-label manufacturing client in the mid-1930s.

Expanding Reach and Customer Base

By the early 1920s, Perrigo's sales force of approximately 50 salesmen served rural stores across the Midwest. This customer base evolved by the mid-1930s, shifting from small general stores to larger regional and national drug chains, indicating a significant expansion in market penetration.

Leveraging Rx-to-OTC Switches and Global Expansion

The advent of prescription-to-over-the-counter (Rx-to-OTC) switches presented substantial growth opportunities, allowing Perrigo to develop store brand versions of popular medications. This era also marked the beginning of Perrigo's international expansion, starting with an acquisition in Mexico in 1997.

IPO and Diversification

Perrigo went public with an Initial Public Offering (IPO) on NASDAQ in 1991, a key step in its capital strategy. The company further diversified its product portfolio into categories like infant formula and animal health, solidifying its position as a growing global consumer products leader. Understanding the strategic decisions behind such growth is crucial, as detailed in the Marketing Strategy of Perrigo Company.

Perrigo Company PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Perrigo's history is marked by significant milestones, strategic acquisitions, and a consistent focus on innovation within the consumer self-care market. The company established itself as a leader in store brand over-the-counter (OTC) products, notably becoming the dominant supplier of OTC acetaminophen in the United States, representing over half of the U.S. volume for this ingredient. This journey reflects a commitment to providing accessible, high-quality health and wellness solutions.

Perrigo's innovation is deeply rooted in its pioneering role in the store brand OTC market, developing manufacturing expertise for affordable alternatives to branded products. The company's strategic acquisitions have consistently broadened its product offerings and global reach, enhancing its ability to serve diverse consumer needs.

Store Brand Dominance

Perrigo pioneered and achieved dominance in the store brand over-the-counter (OTC) market by developing expertise in manufacturing high-quality, affordable alternatives to branded products.

Global Expansion Through Acquisition

Strategic acquisitions, such as those of Agis Industries, Elan Corporation, and Omega Pharma, significantly expanded Perrigo's global footprint and product portfolio, positioning it as a major player in the international consumer self-care landscape.

Focus on Consumer Self-Care

The divestiture of its Generic Rx segment in 2020 marked a pivotal shift, transforming Perrigo into a pure-play consumer self-care company, sharpening its strategic focus on high-margin core categories.

Operational Efficiency Initiatives

The launch of 'Project Energize' in 2024 demonstrates a commitment to enhancing organizational agility and resetting SG&A expenses, with substantial projected savings aimed at strengthening financial performance.

Strategic Portfolio Refinement

Ongoing strategic streamlining, including the planned divestiture of its Dermacosmetics business, underscores Perrigo's dedication to reinforcing its focus on key consumer self-care categories and improving its balance sheet.

Key Product Leadership

Perrigo's leadership in the U.S. OTC acetaminophen market, supplying over half of the nation's volume, highlights its manufacturing capabilities and market penetration in essential self-care products.

Perrigo has navigated significant challenges, including a substantial tax claim from the Irish Revenue Commissioners in 2018 and evolving regulatory dynamics in its infant formula business during fiscal year 2024. The company also faced a class-action lawsuit from shareholders in 1995, demonstrating the inherent risks in its operational and financial landscape.

Tax Dispute Resolution

In 2018, Perrigo faced a significant tax claim of €1.64 billion from the Irish Revenue Commissioners related to a capital gains tax event from a prior acquisition. This presented a considerable financial and legal challenge.

Regulatory and Market Dynamics

The company experienced impacts on its financial results in fiscal year 2024 due to evolving regulatory dynamics within its infant formula business, highlighting the sensitivity of its operations to external market conditions.

Shareholder Litigation

Perrigo encountered a class-action lawsuit from shareholders in 1995, indicating early challenges in managing stakeholder relations and corporate governance during its growth phases.

Strategic Realignment

The company's strategic pivot in 2020 to divest its Generic Rx segment was a direct response to challenges and a move to sharpen its focus, illustrating proactive management in adapting to market pressures and opportunities.

Cost Optimization Efforts

Initiatives like 'Project Energize' are designed to address cost structures and enhance agility, demonstrating a continuous effort to mitigate operational challenges and improve efficiency, as detailed in the Growth Strategy of Perrigo Company.

Portfolio Divestiture Strategy

The planned divestiture of its Dermacosmetics business by Q1 2026 is a strategic move to strengthen the balance sheet and reinforce its focus on high-margin core categories, addressing portfolio complexity and market focus.

Perrigo Company Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The Perrigo company history is a compelling narrative of transformation, beginning with its founding in 1887 and evolving into a global leader in consumer self-care. This brief history of Perrigo showcases its strategic shifts and growth over more than a century.

Future Growth Strategy: The Three-S Plan

Perrigo is focused on its multi-year 'Stabilize, Streamline, and Strengthen' (Three-S) plan. This strategy is designed to drive sustainable growth and enhance overall performance.

Fiscal Year 2025 Projections

For fiscal year 2025, the company projects net sales growth between 1% and 3%. Organic net sales are expected to grow by 2.5% to 4.5%, with adjusted EPS targeted between $2.90 and $3.10.

Long-Term Financial Targets

Over the 2025-2027 period, Perrigo anticipates an organic net sales compound annual growth rate (CAGR) of 2.5%–4.5%. Adjusted EPS CAGR is expected in the high-single to low-double-digit percentage range.

Leverage Reduction and Portfolio Refinement

Perrigo aims to reduce its net leverage to less than 3x adjusted EBITDA by the end of 2025. This will be achieved through earnings growth and portfolio refinement, including the expected divestiture of its Dermacosmetics business by Q1 2026.

Perrigo Company Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔